* Co has lost $65 mln in market cap since Feb rejection of Vitaros (Adds details on options, background, shares) April 16 (Reuters) - Apricus Biosciences Inc said on Monday it was considering options ...
SAN DIEGO, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of ...
(Reuters) - The U.S. Food and Drug Administration on Friday declined to approve Apricus Biosciences Inc's Vitaros, a cream to treat erectile dysfunction, for the second time in a decade, sending the ...
Ferring Pharmaceuticals purchased ex-U.S. assets and rights to Apricus Biosciences’ on-demand topical erectile dysfunction therapy cream Vitaros ® (alprostadil) for potentially $12.7 million. Ferring ...
SAN DIEGO, Feb. 14, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that it has entered into a licensing agreement granting Neopharm Group ("Neopharm" ...
Apricus Biosciences, Inc.APRI announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd. Apricus' share ...
Apricus Biosciences has received European approval to market alprostadil 0.3% topical cream (Vitaros) for the treatment of erectile dysfunction (ED), the company announced today. Vitaros is a ...
(Reuters) - Apricus Biosciences Inc said on Monday it was considering options for the company and looking to sell the U.S. rights to its erectile dysfunction cream Vitaros, after the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results